Added to YB: 2026-01-27
Pitch date: 2026-01-24
KOD [neutral]
Kodiak Sciences Inc.
+4.08%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.
Market Cap
$1.4B
Pitch Price
$25.62
Price Target
N/A
Dividend
N/A
EV/EBITDA
-7.39
P/E
-5.50
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Four Biotechs I’m Watching After the JPM Healthcare Conference - Kodiak Sciences Inc.
KOD (watchlist): Biotech focused on retinal diseases with tarcocimab tedromer, next-gen anti-VEGF designed for extended durability vs current therapies. Phase 3 readout Jan 31, 2026 is make-or-break event. Success could validate platform & position as best-in-class alternative reducing injection frequency. High-stakes binary outcome after prior setbacks.
Read full article (2 min)